Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMA1-DiCo malaria vaccine safety and immunogenicity study
PACTR201402000719423Completed
- Sponsor
- Inserm
- Start
- Jan 2014
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Trial of AMA1-DiCo, GLA-SE adjuvant and aluminium hydroxide in malaria (5 arms), sponsored by Inserm. Primary endpoint: Number of adverse events. Started Jan 2014; status: completed.
02
Drugs
AMA1-DiCoGLA-SE adjuvantaluminium hydroxide
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201402000719423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201402000719423.